Journal of Gastroenterology and Digestive Diseases

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Short Communication - Journal of Gastroenterology and Digestive Diseases (2022) Volume 7, Issue 2

Clinical review on survival rate of early gastric cancer.

Mary T. Jarroit*

Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA

*Corresponding Author:
Mary T. Jarroit
Division of Gastroenterology and Hepatology,
University of North Carolina,
Chapel Hill, North Carolina, USA
E-mail: [email protected]

Received: 17-Jan-2022, Manuscript No. JGDD-22-106; Editor assigned: 19-Jan-2021, PreQC No. JGDD-22-106 (PQ); Reviewed: 02-Feb-2022, QC No. JGDD-22-106; Revised: 09-Feb-2022, Manuscript No. JGDD-22-106 (R); Published: 14-Feb-2022, DOI:10.35841/jgdd-7.2.106

Citation: Jarroit MT. Clinical review on survival rate of early gastric cancer. J Gastroenterology Dig Dis. 2022;7(2):106

Visit for more related articles at Journal of Gastroenterology and Digestive Diseases


Survival data for young adults (YA) with stomach cancer is contradictory and limited. The researchers wanted to see how clinicopathological variables and survival rates differed between younger and older gastric cancer patients. The overall survival rate was not significantly different among the age categories, with the median overall survival being 16 months. The rate of disease-free survival did not differ significantly. The presence of metastatic illness at the time of diagnosis was linked to a higher risk of death for YA. Overall, survival rates were comparable across age groups. The only predictor linked to a worse prognosis in YA was the presence of metastatic disease at the time of diagnosis. These findings show that younger individuals require special attention when it comes to detecting disease at an early stage [1].

Survival and Prognosis- Early Gastric Cancer

Early gastric cancers (EGCs), particularly big and ulcerative lesions, have been treated by endoscopic submucosal dissection (ESD). With median follow-up periods of over 5 years and few published data on the long-term effects of this treatment, we set out to evaluate the long-term outcomes of EGC patients having ESD. Curative ESD for absolute indications, curative ESD for enlarged indications of differentiated-type EGC, and curative ESD for undifferentiated-type EGC, respectively, for pathological curability. Only two individuals suffered recurrence, one of whom acquired a regional lymph node (LN) metastasis and the other of whom developed a distant LN metastasis with local recurrence and died from gastric cancer. Overall survival, disease-specific survival, and relative survival rates after five years. [2].

ESD could be used as a routine treatment for EGC lesions, based on the high 5-year survival rate among EGC patients undergoing curative ESD for absolute or expanded reasons in the biggest patient series with a median follow-up length of over 5 years [2].

Incidence of Gastric Cancer

Varied countries have different rates of GC incidence and mortality. The interaction between Helicobacter pylori (H. pylori) infection and genetic and environmental variables in the host is thought to be the cause of GC. Intestinal gastric adenocarcinoma is caused by H. pylori infection. GC is most widespread in East Asia and East Europe, but considerably less often in Africa; nonetheless, H. pylori infection is common in Africa, which is known as the African enigma. Early GC has a much greater 5-year survival rate than advanced GC. A high incidence of early GC identification could aid in the fight against GC [3].

Survival benefit

Pylorus-preserving gastrectomy (PPG) is a method of treating early gastric cancer in some people. The goal of this study was to look into long-term survival for patients who had PPG with extensive lymph node dissection for early gastric cancer, except for the suprapyloric nodes. If they had cT1 (mucosa or submucosa) and cN0 gastric cancer in the middle body of the stomach, they were eligible for PPG. Retrospective evaluations of overall 5-year survival, cancer-related mortality, and independence from recurrence were conducted. Seven individuals died, with a 98 percent chance of surviving after five years. There was no evidence of tumour recurrence in any of the patients, and no one died from gastric cancer. The accuracy of endoscopy or endoscopic ultrasonography for preoperative diagnosis of T1 stomach cancer was 95.7% [4].


Only when the accuracy of preoperative diagnosis can be ensured, PPG may provide a long-term survival benefit for patients with clinically diagnosed T1 (mucosa or submucosa), cN0 gastric cancer in the middle body of the stomach.


  1. Cormedi MCV, Katayama MLH, Guindalini RSC, et al. Survival and prognosis of young adults with gastric cancer. Clinics (Sao Paulo). 2018;73:e651s.
  2. Indexed at, Google Scholar, Cross ref

  3. Suzuki H, Oda I, Abe S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer. 2016;19(1):198-205.
  4. Indexed at, Google Scholar, Cross ref

  5. Hu Y, Fang JY, Xiao SD. Can the incidence of gastric cancer be reduced in the new century? J Dig Dis. 2013;14(1):11-5.
  6. Indexed at, Google Scholar, Cross ref

  7. Hiki N, Sano T, Fukunaga T, et al. Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg. 2009;209(3):297-301.
  8. Indexed at, Google Scholar, Cross ref

Get the App